To assess links between CSF αSyn levels and AD brain pathology using surrogate CSF AD biomarkers in the DIAN participants we investigated potential correlations between CSF αSyn and CSF levels of Aβ1–42, Aβ1–40, Aβ42/40, t-tau, and p-tau in ADAD non-mutation carriers and the three ADAD mutation carrier groups sorted into asymptomatic and symptomatic subgroups (the n = 2 PSEN1 symptomatic patient group was excluded from analysis) (Table 4). The gene discussed is MAPT; the disease is Alzheimer disease.